FHC
SAGE

First Horizon Corporation’s Sage Therapeutics SAGE Stock Holding History

First Horizon Corporation’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$2K Hold
52
– – ﹤0.01% 964
2021
Q1 		$3K Buy
+52
New +$4.26K ﹤0.01% 894

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

First Horizon Corporation's SAGE Position: Q2 2021 in Review

First Horizon Corporation held its Sage Therapeutics (SAGE) position steady in Q2 2021 at 52 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #964.

First Horizon Corporation first reported a position in SAGE in Q1 2021 and has held it in 2 quarters since. The position peaked at $3K in Q1 2021. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • First Horizon Corporation held 52 shares of Sage Therapeutics worth $2K as of Q2 2021.
  • First Horizon Corporation left its Sage Therapeutics share count unchanged in Q2 2021.
  • Sage Therapeutics made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2021, its #964 holding.
  • First Horizon Corporation first reported a position in Sage Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • First Horizon Corporation's Sage Therapeutics position peaked at $3K in Q1 2021.
  • 256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on First Horizon Corporation's 13F filing for Q2 2021, filed 9 Aug 2021.